Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2003-08-18
2010-11-02
Angell, J. E (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07825235
ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 2 are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini
patent: 5837542 (1998-11-01), Grimm et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6083695 (2000-07-01), Hardin et al.
patent: 6100077 (2000-08-01), Sturley et al.
patent: 6127533 (2000-10-01), Cook
patent: 6284538 (2001-09-01), Monia et al.
patent: 6344548 (2002-02-01), Farese, Jr. et al.
patent: 6444427 (2002-09-01), Ludwig et al.
patent: 6512099 (2003-01-01), Omura et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6605451 (2003-08-01), Marmaro et al.
patent: 6607893 (2003-08-01), Ramharack et al.
patent: 6822141 (2004-11-01), Lardizabal et al.
patent: 7250496 (2007-07-01), Bentwich
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2002/0119138 (2002-08-01), Cases et al.
patent: 2002/0127627 (2002-09-01), Ramharack et al.
patent: 2002/0193315 (2002-12-01), Omura et al.
patent: 2003/0028923 (2003-02-01), Lardizabal et al.
patent: 2003/0073103 (2003-04-01), Ludwig et al.
patent: 2003/0100480 (2003-05-01), Smith et al.
patent: 2003/0104414 (2003-06-01), Attersand
patent: 2003/0115632 (2003-06-01), Lardizabal et al.
patent: 2003/0124126 (2003-07-01), Cases et al.
patent: 2003/0152574 (2003-08-01), Logan et al.
patent: 2003/0161831 (2003-08-01), Cases et al.
patent: 2003/0170691 (2003-09-01), Gimeno et al.
patent: 2003/0200563 (2003-10-01), Butler et al.
patent: 2003/0202968 (2003-10-01), Cases et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2004/0054177 (2004-03-01), Otake et al.
patent: 2004/0058820 (2004-03-01), Hagmann et al.
patent: 2004/0097459 (2004-05-01), Dobie et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 1 308 459 (2003-05-01), None
patent: WO 00/78961 (2000-12-01), None
patent: WO 01/68848 (2001-09-01), None
patent: WO 01/77389 (2001-10-01), None
patent: WO 01/92512 (2001-12-01), None
patent: WO 02/08260 (2002-01-01), None
patent: WO/02/068595 (2002-09-01), None
patent: WO/03/053363 (2003-07-01), None
Melo et al. Trends in Molecular Medicine, 2005; vol. 11, No. 5, pp. 240-250.
Vaughan et al. Current Opinons in Cardiology, 2001; vol. 16, pp. 195-200.
Buhman et al., DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis,J. Biol. Chem., 2002, 277:25474-25479.
Cases et al., Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis,Proc. Natl. Acad. Sci. U. S. A., 1998, 95:13018-13023.
Cases et al., Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members,J. Biol. Chem., 2001, 276:38870-38876.
Chen et al., Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1,J. Clin. Invest., 2002, 109:1049-1055.
Chen et al., Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands,J. Clin. Invest., 2002, 109:175-181.
Farese et al., Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase,Curr. Opin. Lipidol., 2000, 11:229-234.
Lardizabal et al., DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect cells of two polypeptides fromMortierella ramannianawith diacylglycerol acyltransferase activity,J. Biol. Chem., 2001, 276:38862-38869.
Meegalla et al., Concerted elevation of acyl-coenzyme A:diacylglycerol acyltransferase (DGAT) activity through independent stimulation of mRNA expression of DGAT1 and DGAT2 by carbohydrate and insulin,Biochem. Biophys. Res. Commun., 2002, 298:317-323.
Oelkers et al., Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes,J. Biol. Chem., 1998, 273:26765-26771.
Smith et al., Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat,Nat. Genet., 2000, 25:87-90.
Waterman et al., Distinct ontogenic patterns of overt and latent DGAT activities of rat liver microsomes,J. Lipid. Res., 2002, 43:1555-1562.
Cheng et al., “Human acyl-CoA: diacylglycerol acyltransferase is a tetrameric protein”,Biochem. J. Nov. 1, 2001 359(pt 3):707-714.
Ludwig et al., “DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women”,Clin. Genet. Jul. 2002 62(1):68-73.
Tabata et al., “Xanthohumols, diacylglycerol acyltransferase inhibitors, fromHumulus lupulus”, PhytochemistryOct. 1997 46(4):683-687.
Tomoda et al., “Roselipins, inhibitors of diacylglycerol acyltransferase, produced byGliocladium roseumKF-1040”,J. Antibiot. (Tokyo) Aug. 1999 52(8):689-694.
Yu et al., “Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes”,J. Biol. Chem. Dec. 27, 2002 277(52):50876-50884.
Chin, Andrew “On the Preparation and Utilization of Isolated and Purified Oligonucleotides.” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
The European Supplementary European Search Report dated Jul. 4, 2008 (EP 04 77 9444).
Branch et al., “A good antisense molecule is hard to find” TIBS (1998) 23:45-50.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
Desai et al., “Phenotypic Correction of Diabetic Mice by Adenovirus-Mediated Glucokinase Expression” Diabetes (2001) 50:2287-2295.
Guo et al., “par-1, a Gene Required for Establishing Polarity inC. elegansEmbryos, Encodes a Putative Ser/Thr Kinase that is Asymmetrically Distributed” Cell (1995) 81:611-620.
Montgomery et al., “RNA as a target of double-stranded RNA-mediated genetic interference inCaenorhabditis elegans” Proc. Natl Acad. Sci. (1998) 95:15502-15507.
New England Biolabs 1998/1999 Catalog, cover page, pp. 121 and 284.
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3):326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Stone et al., “Lipopenia and Skin Bather Abnormalities in DGAT2-deficient Mice” J. Biol. Chem. (2004) 279(12):11767-11776.
Tijsterman et al., “RNA Helicase MUT-14-Dependent Gene Silencing Triggered inC. elegansby Short Antisense RNAs” Science (2002) 295:694-697.
Yu et al., “Antisense Oligonucleotide Inhibition of DGAT2 Expression Reduced Hepatic Steatosis and Hyperlipidemia in Diet-Induced Obese Mice” Obesity Res. (2003) NAASO's 2003 Annual Meeting, Oct. 11-15, 11:A48.
Yu et al., “Antisense Oligonucleotide Reduction of DGAT2 Expression Improves Hepatic Steatosis and Hyperlipidemia in Obese Mice” Hepatology (2005) 42:362-371.
International Search Report for Int. Application No. PCT/USO4/24384 dated Mar. 23, 2006.
Office Action for U.S. Appl. No. 11/066,725 dated Mar. 8, 2007.
Office Action for U.S. Appl. No. 11/066,725 dated Aug. 18, 2008.
Office Action for U.S. Appl. No. 11/066,725 dated Feb. 4, 2009.
Final Rejection for U.S. Appl. No. 11/066,725 dated Sep. 25, 2007.
Bhanot Sanjay
Dobie Kenneth W.
Monia Brett P.
Yu Xing-Xian
Angell J. E
Isis Pharmaceuticals , Inc.
McDermott Will & Emery LLP
LandOfFree
Modulation of diacylglycerol acyltransferase 2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of diacylglycerol acyltransferase 2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of diacylglycerol acyltransferase 2 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4216823